Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
April 23 2024 - 4:15PM
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery
and development stage specialty pharmaceutical company focused on
improving the outcomes of cancer patients treated with radiation
therapy (“RT”), today announced that its Chief Executive Officer,
Dr. Anatoly Dritschilo, will present at the Planet MicroCap
Showcase: VEGAS 2024, on Wednesday, May 1, 2024 at 4:30pm PT. The
Company will also host in person one-on-one meetings with investors
on Thursday, May 2, 2024.
Dr. Dritschilo’s presentation will include an
update on the Company's progress toward clinical and scientific
milestones of its Phase 2 Clinical Trial of Ropidoxuridine for
treatment of patients with glioblastoma, a deadly malignancy of the
brain with no known cure. Additionally, he will provide an update
on the Company’s plans of its subsidiary, Shuttle Diagnostics,
Inc., to develop predictive biomarkers for prostate cancer outcomes
following radiation therapy, and novel PSMA ligand for theranostic
applications.
Planet MicroCap Showcase: VEGAS
2024
Conference Location: Paris
Hotel & Casino in Las Vegas, NV
Presentation Date: Wednesday,
May 1, 2024
Presentation Time: 4:30pm PT
(7:30pm ET)
Presentation Webcast: The
webcasted presentation can be accessed at
https://www.webcaster4.com/Webcast/Page/3026/50183 or on the
Company's website at https://shuttlepharma.com/investor-relations/.
The webcast will also be available for replay following the
event.
1x1 Meetings: Management will
be participating in in-person one-on-one meetings at the event on
Thursday, May 2, 2024. To arrange a meeting with management, please
contact your Planet MicroCap representative, or Lytham Partners at
SHPH@lythampartners.com.
About Shuttle
PharmaceuticalsFounded in 2012 by faculty members of the
Georgetown University Medical Center, Shuttle Pharmaceuticals is a
discovery and development stage specialty pharmaceutical company
focused on improving the outcomes for cancer patients treated with
radiation therapy (“RT”). Our mission is to improve the lives of
cancer patients by developing therapies that are designed to
maximize the effectiveness of RT while limiting the side effects of
radiation in cancer treatment. Although RT is a proven modality for
treating cancers, by developing radiation sensitizers, we aim to
increase cancer cure rates, prolong patient survival and improve
quality of life when used as a primary treatment or in combination
with surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Forward-Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may relate to statements concerning
future results, strategy and plans of the Company (including
certain statements which may be identified by the use of the words
“plans,” “expects,” “does not expect,” “estimated,” “is expected,”
“budget,” “scheduled,” “estimates,” “forecasts,” “intends,”
“anticipates,” “does not anticipate” or “believes,” or variations
of such words and phrases, or state that certain actions, events or
results “may,” “could,” “would,” “might,” “projects,” “will,” “will
be taken,” “occur” or “be achieved”). Forward-looking statements
are based on the opinions and estimates of management of the
Company, as of the date such statements are made, and they are
subject to known and unknown risks, uncertainties, assumptions and
other factors that may cause the actual results, performance or
achievements to be materially different from those expressed or
implied by such forward-looking statements. Additional information
on these and other factors that may cause actual results and the
Company’s performance to differ materially is included in the
Company’s periodic reports filed with the SEC, including, but not
limited to the Company’s Annual Report on Form 10-K for the year
ended December 31, 2023, and subsequent Quarterly Reports on Form
10-Q. Copies of the Company’s filings with the SEC are available
publicly on the SEC’s website at www.sec.gov. Readers are cautioned
not to place undue reliance upon any forward-looking statements,
which speak only as of the date made. These forward-looking
statements are made only as of the date hereof, and the Company
undertakes no obligations to update or revise the forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Shuttle PharmaceuticalsAnatoly Dritschilo,
M.D., CEO240-403-4212info@shuttlepharma.com
Investor ContactsLytham Partners, LLCRobert
Blum 602-889-9700shph@lythampartners.com
Shuttle Pharmaceuticals (NASDAQ:SHPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shuttle Pharmaceuticals (NASDAQ:SHPH)
Historical Stock Chart
From Jul 2023 to Jul 2024